Compare AG & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AG | HRMY |
|---|---|---|
| Founded | 1979 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 1.8B |
| IPO Year | 2004 | 2020 |
| Metric | AG | HRMY |
|---|---|---|
| Price | $16.90 | $32.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $21.92 | ★ $44.11 |
| AVG Volume (30 Days) | ★ 11.7M | 731.1K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.12% | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 0.55 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | $24.41 | $19.75 |
| Revenue Next Year | $10.68 | $12.88 |
| P/E Ratio | $143.01 | ★ $59.93 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $7.74 | $25.52 |
| 52 Week High | $32.00 | $40.87 |
| Indicator | AG | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 33.76 | 57.60 |
| Support Level | $15.54 | $31.61 |
| Resistance Level | $17.37 | $33.11 |
| Average True Range (ATR) | 1.09 | 0.90 |
| MACD | -0.24 | 0.17 |
| Stochastic Oscillator | 0.80 | 74.08 |
First Majestic Silver Corp is in the business of production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. The company owns four producing mines in Mexico, consisting of the Santa Elena Silver/Gold Mine, the San Dimas Silver/Gold Mine, the Los Gatos Silver Mine, and the La Encantada Silver Mine. It also owns the Jerritt Canyon Gold Mine in Nevada, USA. Additionally, the firm holds interests in the San Martin Silver Mine and the Del Toro Silver Mine, and several exploration-stage projects. The majority of the company's revenues are from the sale of precious metals contained in dore and concentrate form. It generates maximum revenue from the sale of silver, followed by gold, zinc, copper, and other metals.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.